AOCI at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's AOCI?
- NewAmsterdam Pharma Company (NAMS) reported AOCI of $4.22M in Q1 2026.
- How has NewAmsterdam Pharma Company's AOCI changed year-over-year?
- NewAmsterdam Pharma Company's AOCI decreased by 4.8% year-over-year, from $4.43M to $4.22M.
- What is the long-term trend for NewAmsterdam Pharma Company's AOCI?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's AOCI has grown at a 2.7% compound annual growth rate (CAGR), from $4.42M to $4.79M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.